《新股》四环医药(00460.HK)建议分拆轩竹生物在港上市

阿斯达克财经
26 Nov 2024

四环医药(00460.HK) 公布,建议分拆轩竹生物于联交所主板独立上市其H股,联交所已确认公司可进行建议分拆。轩竹生物拟通过全球发售方式发售其H股,全球发售详情尚未落实。
四环医药表示,截至昨日(25日),四环医药间接拥有轩竹生物56.47%股份。按计划,于建议分拆及上市完成后,轩竹生物将仍为四环医药的附属公司。轩竹生物昨日向联交所提交上市申请表格,申请分拆公司的H股于联交所主板上市及买卖。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-25 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10